Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Ziprasidone in bipolar disorder.

Marcio Versiani¹

¹Bipolar Disorders Program, Institute of Psychiatry, Federal University of Rio de Janeiro, R. Visconde de Pirajá 407 s.805, Rio de Janeiro, 22410-003, Brazil. marcio.versiani@terra.com.br

Expert Opinion on Pharmacotherapy

|May 31, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A 6-Year Posttreatment Follow-up of Panic Disorder Patients: Treatment With Clonazepam Predicts Lower Recurrence Than Treatment With Paroxetine.

Journal of clinical psychopharmacology·2017

Same author

Gender effect on clinical features and drug treatment response in social anxiety disorder (social phobia).

International journal of psychiatry in clinical practice·2014

Same author

Correlates of insight into different symptom dimensions in obsessive-compulsive disorder.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists·2013

Same author

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

European archives of psychiatry and clinical neuroscience·2012

Same author

A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine.

Journal of clinical psychopharmacology·2011

Same author

Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders.

European archives of psychiatry and clinical neuroscience·2011

Ziprasidone, an antipsychotic, effectively treats bipolar mania and schizophrenia. It shows sustained efficacy, is well-tolerated, and does not negatively impact weight, glucose, or lipid levels in bipolar disorder patients.

Area of Science:

Psychiatry
Pharmacology

Background:

Ziprasidone is a second-generation antipsychotic used for schizophrenia and bipolar mania.
It possesses a unique receptor binding profile, including antagonist activity at 5-HT2A and D2 receptors, and agonist activity at 5-HT1A receptors.

Purpose of the Study:

To evaluate the efficacy and tolerability of ziprasidone in treating bipolar mania.
To assess its long-term effectiveness and safety in bipolar disorder patients.

Main Methods:

Multiple placebo-controlled trials were conducted to assess ziprasidone's efficacy in acute manic or mixed episodes.
A three-arm study compared ziprasidone, haloperidol, and placebo.
Open-label studies evaluated long-term treatment up to 52 weeks, and combination therapy with lithium was also investigated.

Related Experiment Videos

Main Results:

Ziprasidone demonstrated efficacy in bipolar mania, including dysphoric mania, across placebo-controlled trials.
Sustained efficacy was observed in open-label treatment for up to 52 weeks.
Combination therapy with lithium showed sustained efficacy in acute mania treatment for up to 1 year.

Conclusions:

Ziprasidone is an effective treatment for bipolar mania with sustained efficacy.
The drug is well-tolerated in patients with bipolar disorder, showing no adverse effects on weight, glucose, or lipid levels.